The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols by Calvert, Melanie et al.
 
 
The patient-reported outcome content of
international ovarian cancer randomised controlled
trial protocols
Calvert, Melanie; Kyte, Derek; Mercieca-bebber, Rebecca; King, Madeleine T.
DOI:
10.1007/s11136-016-1339-x
License:
None: All rights reserved
Document Version
Peer reviewed version
Citation for published version (Harvard):
Calvert, M, Kyte, D, Mercieca-bebber, R & King, MT 2016, 'The patient-reported outcome content of international
ovarian cancer randomised controlled trial protocols', Quality of Life Research, vol. 25, no. 10, pp. 2457–2465.
https://doi.org/10.1007/s11136-016-1339-x
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
The final publication is available at Springer via http://dx.doi.org/10.1007/s11136-016-1339-x
Embargo date confirmed 27/10/16
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
Article Title: 
The patient-reported outcome content of international ovarian cancer randomised 
controlled trial protocols 
Authors:  
Rebecca Mercieca-Bebber1,2, Michael Friedlander3,4,  Peey-Sei Kok3,4, Melanie Calvert5, Derek 
Kyte5, Martin Stockler3, Madeleine T. King1,2, 4 
Affiliations:  
1 Central Clinical School, Sydney Medical School, University of Sydney, NSW 2006, Australia. 
2 Psycho-oncology Co-operative Research Group, School of Psychology, University of Sydney. 
Level 6 North, Chris O’Brien Lifehouse C39Z, University of Sydney, NSW 2006, Australia. 
3 NHMRC Clinical Trials Centre, University of Sydney, NSW 2006. 
4 Australian New Zealand Gynecological Oncology Group (ANZGOG), Camperdown, NSW 
2050. 
5Institute of Applied Health Research, University of Birmingham, Birmingham, United 
Kingdom. 
Corresponding author: 
 Rebecca Mercieca-Bebber 
Quality of Life Office 
Level 6 North, Lifehouse (C39Z) 
University of Sydney, NSW 2006 
Australia 
 Email: Rebecca.mercieca@sydney.edu.au 
 Phone: +612 9114 1365 
 Fax: +612 9036 5292 
Key words: 
Quality of life, patient-reported outcomes, protocol checklist, ovarian cancer, clinical trials as 
topic, guideline adherence 
The patient-reported outcome content of international ovarian cancer randomised controlled trial 
protocols 
Abstract:  
Purpose 
Patient-reported outcomes (PROs) provide the patient’s perspective of the impact of treatment.  
Evidence suggests that PRO content of randomised controlled trials (RCT) protocols is generally 
suboptimal. This study aimed to describe and evaluate the PRO-specific content of ovarian cancer 
RCT protocols.  
Methods  
Published, phase III, ovarian cancer RCTs with PRO endpoints were identified following a systematic 
search of Medline and Cochrane databases (Jan 2000-Feb 2016). Corresponding RCT protocols were 
downloaded (if published) or obtained by contacting authors. Two investigators independently 
assessed adherence of PRO-specific content of included protocols to a checklist of 58 recommended 
PRO protocol items currently being developed by the International Society for Quality of Life 
Research (ISOQOL). Discrepancies were resolved with a third investigator. 
Results  
Of 41 eligible trials identified, 26 protocols were assessed (developed 1995-2010). We were unable 
to obtain the remaining 15 protocols. Protocols addressed a mean of 28% PRO checklist items (range 
8-66%).  Fifteen (58% of assessed protocols) provided a rationale for PRO assessment, 8 (31%) 
described a PRO objective, 24 (92%) included a PRO assessment schedule, but only 6 (23%) justified 
timing of PRO assessments. Twelve protocols (46%) provided staff data collection instructions, 4 
(15%) included plans for monitoring PRO compliance and 16 (62%) included a PRO analysis plan.  
Conclusions 
On average, protocols addressed less than one-third of PRO protocol checklist items. In some cases, 
key guidance regarding PRO administration was lacking, which may lead to inconsistent and sub-
optimal PRO methodology. Efforts are needed to improve PRO protocol content in cancer trials. 
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The patient-reported outcome content of international ovarian cancer randomised 
controlled trial protocols. 
 
Quality of life (QOL) and other patient-reported outcomes (PROs) are important endpoints in ovarian 
cancer randomised controlled trials (RCTs), as the disease and its treatment can result in significant 
morbidities [1]. PROs are particularly important in patients with recurrent ovarian cancer where 
survival time is relatively short [1]. The average five-year survival rate for ovarian cancer is 
approximately 44-46% and there has been very little improvement in survival over the past 30 years 
[2,3]. PRO data are therefore crucial in evaluating the effectiveness or superiority of a therapeutic 
intervention, determining whether the treatment improves cancer-related symptoms or has 
acceptable toxicity as assessed by patients[4]. Accordingly, PROs have been included as secondary 
endpoints in ovarian cancer RCTs for many years [5]. However, the methodological quality of these 
PRO studies has, to our knowledge, never been scrutinised. 
A comprehensive, high-quality protocol is critical in ensuring rigorous methodology for all RCT 
endpoints, including PROs [6,7]. The protocol is a key document for communicating the research 
rationale, standardised methodology, and ethical considerations to trial investigators and data 
collection staff [6]. For this reason, the quality of trial protocols is closely scrutinised by trial 
sponsors, ethics committees and increasingly by the broader research community when made 
accessible through publication or trial registration [8]. Given that RCTs are unlikely to be replicated, 
it is crucial that PRO studies are carefully planned, and that these plans are clearly and 
comprehensively described in the protocol, to yield meaningful and high-quality PRO research 
evidence [7]. 
It is of concern, therefore, that a recent review of PRO content of trial protocols in the United 
Kingdom found that on average, only a third of recommended PRO protocol content was addressed 
[9]. The study sample included RCTs from a range of health disciplines, but only four from oncology. 
The main objective of the present study was to describe and evaluate the PRO-specific content of 
ovarian cancer RCT protocols against a checklist of recommended protocol items for PRO endpoints 
in RCTs. 
Methods  
Identification of RCTs 
Published, phase III, ovarian cancer RCTs of biomedical interventions with PRO endpoints were 
identified using three methods: 1) a systematic search of Medline and Cochrane Clinical Trials 
databases from 1 January 2000 - 1 February 2016 for relevant publications (see Appendix 1 for the 
full search strategy, which was developed with assistance from a librarian); 2) searching reference 
lists of included papers for additional, relevant RCTs; and 3) contacting the Gynaecologic Cancer 
Inter-Group (GCIG) Symptom Benefit Working Group (SBWG) to identify any additional published 
RCTs.  
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In order to maintain a focus on high-quality biomedical ovarian cancer RCTs for which PRO evidence 
may impact clinical practice, we excluded RCTs of mixed cancer samples (i.e. ovarian + other cancer 
types), samples of <50 patients, and complementary, alternative and psychological interventions. 
We also excluded non-English publications to avoid potential translation bias. We restricted to 
published RCTs, rather than searching trial registries for eligible trials, as these protocols will be 
included in a separate subsequent analysis involving both the publication and protocol of each RCT. 
RCT protocols were downloaded from the journal’s website when published as an appendix to the 
RCT manuscript or obtained by contacting (by email) corresponding authors of the RCT publications. 
Failure to respond to two emails, sent up to six months apart, was considered non-response. We 
were able to identify alternative email addresses for some corresponding authors via clinical 
networks after the contact email noted on the RCT publication had bounced. RCT authors were 
assured that protocols would be de-identified in analyses and publications to encourage 
participation, and for the benefit of education and quality improvement of future protocols.  This 
was intended to minimise risk of original protocols being “improved” for evaluation. RCT authors 
were not provided with a copy of the PRO protocol checklist used for the same reason. 
Protocol evaluation  
Two authors (RMB, PK) independently reviewed the PRO-specific content of protocols against a 
checklist of recommended PRO protocol items (Appendix 2). The draft checklist content was derived 
from a previous systematic review [10] and is currently being refined by the International Society for 
Quality of Life Research (ISOQOL) Taskforce for Best Practices for PROs. Ultimately the ISOQOL 
Taskforce aims to develop a PRO-specific extension to the SPIRIT 2013 Statement (Standardised 
Protocol Items for Randomised Trials) [6,11,7].  The PRO protocol checklist includes 58 items: 56 
relating to PRO-specific content of the main protocol (e.g. rationale for including PROs, assessment 
time points, PRO measures, planned analyses, etc.); and two general items (identification of PRO 
sections of the protocol in table of contents and provision of references for key PRO statements). 
Item P17 of the checklist  (sample size for the PRO study) is directed only to RCTs with a primary PRO 
endpoint, however we assessed all protocols for this item regardless of PRO endpoint status, as we 
noticed early on (and wanted to document) that many of the protocols with secondary PRO 
endpoints had addressed PRO sample size. 
The checklist also includes six items related to the PRO-specific content of protocol appendices. For 
each included protocol, a score of 1 was allocated to each PRO checklist item completely addressed, 
0.5 to items partially addressed, 0 to items not addressed, and ‘not applicable’ (N/A) was recorded 
when appropriate.  A total score for the main sections of each protocol (i.e. excluding the 
appendices) was calculated and converted to a percentage using a denominator of 58 minus the 
number of ‘N/A’ items, if any. Protocol appendices were analysed separately, as an appendix was 
not evaluable for all RCTs. 
Inter-rater agreement was calculated using Cohen’s Kappa statistic. Scoring was compared at regular 
intervals to ensure consistent and accurate interpretation of checklist items. Some checklist items 
required discussion to clarify meaning, including Item P17 (as described above); Item P9 (we 
accepted statements identifying PROs as a secondary endpoint, regardless of whether or not PROs 
were identified as a ‘key’ secondary endpoint); and P45 (we interpreted ‘response rates’ in this 
context as the proportion of returned questionnaires required for valid analysis, rather than clinical 
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response rate or change in PRO scores). Scoring discrepancies were resolved through discussion with 
a senior investigator (MK, MC, or MF). We tested the null hypothesis that PRO protocol checklist 
scores would not improve over time by calculating Spearman correlation using a pre-specified alpha 
level of 0.05. We also ran a series of exploratory t-tests (post-hoc) to determine whether there were 
differences in mean protocol checklist score for international studies (Y/N), commercial sponsorship 
(Y/N) and trials group sponsorship (Y/N), using a Bonferroni adjusted alpha of p=017. All analyses 
were conducted using SPSS (Version 22, Armonk, NY: IBM Corp).  
Results  
Figure 1 summarises the RCT selection process. Of 41 eligible trials identified, 26 protocols were 
assessed (8 published, 18 provided by authors). The remaining 15 could not be obtained (9 non-
response, four email bounces, one refusal, and for one, a report was sent to us rather than the 
protocol). Inter-rater agreement was excellent (κ = .87, p<0.001).  
<<Insert Figure 1 about here>> 
 
Characteristics of 26 included protocols 
Characteristics of 26 included protocols are included in Table 1. Protocols were developed between 
1995 and 2010. Year of development was not stated for two protocols. Eleven protocols were for 
international RCTs (national RCTs n=7, unclear n=4). Twenty-four had a secondary PRO endpoint and 
one RCT had a co-primary PRO endpoint (with progression-free survival (PFS)); the status of the PRO 
endpoint in one RCT was unclear. The majority of RCTs had a primary endpoint of PFS (n=16), and 
were of chemotherapy (n=21). The most commonly used PRO measure was the European 
Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 
(QLQ-C30, n=19) and ovarian cancer module (QLQ-OV28) (n=11). 
<<Insert Table 1 about here>> 
PRO Protocol Checklist items not relevant and excluded  
Two PRO Protocol Checklist items were not relevant to any protocols in the sample and were rated 
N/A: none of the protocols included a validation study for PRO measures (Item P21) or permitted 
proxy assessment (P26). Only five protocols administered PROs to a sub-sample, therefore the item 
requesting justification of sampling method (P6) was only applicable to these five protocols. The 
item describing order of administration of multiple PRO measures (P29) was not applicable to the 19 
trials that used EORTC measures (where the administration order is standardised: QLQ-C30 then 
QLQ-OV28), or only one PRO measure. Twelve protocols each had three N/A items and the 
remaining 14 protocols had four N/A items. This reduced the highest possible PRO protocol checklist 
total score (i.e. denominator) to 55 or 54 respectively. 
PRO-specific content of protocols  
Protocols addressed a mean of 28% (SD 13.7%) applicable PRO checklist items (excluding 
appendices), with scores ranging from 8 – 66%. Only two protocols (developed in 2004 and 2005) 
addressed more than 50% of recommended items, and 50% of the 26 protocols scored between 20-
40%. PRO protocol checklist total scores are summarised in Table 2. There was a trend towards total 
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PRO protocol checklist scores improving overtime, however it was not statistically significant: r 
=0.37, p=0.07 [95% CI -0.35, 0.68] (see Appendix 3). There were no significant differences in PRO 
protocol checklist score for international compared to national RCTs (p=0.93), commercial 
sponsorship (p=0.14) or trials group sponsorship (p=0.28). 
<<Insert Table 2 about here>> 
 
The PRO-specific content of included protocols, including the number of protocols addressing each 
checklist item in full or partially, is graphed by order of adherence frequency in Figure 2. Briefly, 15 
protocols (58% of the assessed protocols) provided a rationale for assessing PROs, but only eight 
(31%) described a PRO objective. Twenty-four (92%) included a PRO assessment schedule, but only 
six (23%) justified timing and 6 provided acceptable assessment windows. Twelve protocols (46%) 
provided staff data collection instructions and six encouraged staff discussion with patients of the 
importance of PRO assessments. Only four (15%) included plans for monitoring PRO compliance. 
Sixteen (62%) included some form of PRO analysis plan, but only nine (35%) stated how missing data 
would be described and two (8%) included plans for controlling for multiplicity.  
<<Insert Figure 2 about here>> 
Protocol appendices 
Five protocols (19%) included a sample of the patient information sheet, which addressed the PRO 
study, four (15%) included a standardised form for collecting reasons for missing PRO data, 16 (62%) 
included a copy of the PRO measure being used, and five (19%) included evidence of permission to 
use the measure. 
Discussion 
Summary of findings 
This study evaluates the PRO-specific content of ovarian cancer trial protocols; a patient cohort for 
which PROs have long been considered important endpoints in comparative effectiveness research. 
On average, protocols addressed less than one-third of recommended PRO checklist items. This low 
total score suggests that, on average, some potentially important PRO guidance is missing from 
protocols.  
It is concerning that only 31% of protocols included a clear PRO objective, 19% included a PRO-
specific hypothesis, 23% justified timing of assessment and 58% justified the PRO measure used.  
These are crucial to good PRO study design; they require thoughtful planning to reliably capture 
treatment effects and enable meaningful comparisons between treatment arms, and accordingly, 
need to be addressed in the protocol. If the PRO measure used is not sensitive to treatment 
toxicities, or if the timing of assessment is not scheduled to capture relevant toxicities, any real 
differences between groups or clinically important treatment effects may not be understood by the 
PRO assessment. Ultimately, PRO design decisions impact what treatments are approved for use and 
offered to patients, therefore the methodology must be carefully justified in the protocol. 
Regulatory bodies, such as the Food and Drug Administration (FDA) and European Medical 
Association (EMA) recognise the value and importance of high-quality PRO assessment in the 
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therapeutic approval process, and accordingly offer PRO assessment guidance [12-14].  Likewise, the 
Cochrane handbook offers clear guidelines for assessing the PRO evidence of intervention research 
in the context of conducting a systematic review [15].  We note that these guidelines (although 
targeted to trial publications) marry with the PRO protocol checklist used in the present study; 
demonstrating that trial design considerations relevant to the protocol are also relevant to 
publications. 
Whilst the majority of protocols included basic PRO information, such as identifying the PRO as a 
primary or secondary endpoint (92%), specifying the assessment schedule (96%) and describing the 
PRO measure (85%), other key details required for standardising PRO methodology were often not 
addressed. For example, 54% stated whether baseline PRO assessment should occur before 
randomisation, only 27% provided acceptable PRO assessment time windows and 46% stated where 
questionnaires should be completed. PRO assessments taken a day before administration of 
chemotherapy are likely to differ from those taken a day or a week after chemotherapy due to 
differences in toxicity, and whether or not the targeted days are captured by the questionnaire’s 
recall period [16]. Additionally, if baseline PRO assessment occurs after the intervention has 
commenced, the assessment may be invalid if the intervention impacts PRO scores.  Some experts 
also recommend standardisation of assessment timing relative to the patient’s appointment with 
their clinician, so that news of disease status does not impact PRO scores; yet only 54% of protocols 
addressed this. Our findings are concerning because lack of clear protocol guidance could lead to 
variation in PRO measurement practice, which may increase variability in the PRO data and 
potentially lead to bias [7,17]. Central PRO compliance monitoring is a useful strategy for identifying 
potential issues in real-time, to enable timely intervention and to avoid persistent problems, yet only 
12% of protocols described PRO-specific monitoring procedures.  
Recent evidence suggests that data collection staff often find PRO guidance inadequate [17]. Few 
protocols addressed staff training (8%), specified who should administer PROs (42%) or included 
guidance for discussing PRO assessments with patients (35%). Failure to address these points in the 
protocol does not necessarily imply failure to educate staff or patients within the trial, but possibly 
suggests that education was not standardised, and may in some cases have been insufficient[17]. A 
recent review of strategies to minimise avoidable missing PRO data highlighted the importance of 
educating staff and patients about the importance of PROs [18], thus staff and patient education 
about PROs is an important quality assurance concern. 
Only two protocols (8%) noted PRO data would not inform patient care and no protocols included a 
“PRO alerts” strategy for consistent management of concerning PRO data requiring an immediate 
response, such as psychosocial referral for high anxiety scores[19]. Without clear guidance, staff may 
use their own judgment, which is likely to differ between individuals, to determine whether they 
examine PRO data for concerning scores, and whether and how they act on that data [20]. This may 
lead to co-intervention bias if their intervention impacts future PROs scores[20]. 
The present cohort of protocols was older (developed 1995-2010) than the protocols studied by Kyte 
and colleagues (2012-2013)[9], the checklists differed slightly, as did the disease focus (the present 
study focuses on ovarian cancer protocols; Kyte’s study included trials (any disease) funded by UK 
National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme). 
Although average protocol completeness scores were similar (marginally higher in Kyte’s study: 33% 
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compared to 28%), there were some key differences in findings between reviews. For example only 
8% of the HTA protocols (compared to 58% of the ovarian cancer protocols) included a rationale for 
PRO assessment; 45% of the HTA cohort included PRO-specific eligibility criteria compared to only 
8% of the ovarian cohort, and approximately 11% of HTA (compared to zero ovarian cancer) 
protocols addressed management of PRO alerts[9]. It is unclear exactly what factors contributed to 
differences in protocol content between the two cohorts. However, it is worth noting that the 
systematic review that sourced PRO protocol checklist content included a large proportion of 
guidance sourced from oncology [10]; possibly suggesting that PRO-specific guidance differs 
between medical specialisations. Alternatively, differences may reflect the changing nature of PRO 
assessment overtime.   
We anticipated that more recent ovarian cancer RCT protocols would score higher than older 
protocols due to an increased need for specific details. For instance, in older trials it is likely that only 
paper-based PRO assessment was possible, therefore there was little need to state mode of 
administration in the protocol until recently, with increased use of electronic PRO assessment. 
Technological advances have enabled real time scoring of PRO data, allowing PRO data summaries to 
inform care in previously infeasible ways, for example by making automated PRO alerts possible. Our 
findings suggest that protocol completeness slightly improved with time, however the finding was 
not statistically significant. The trend we observed towards higher scores overtime was likely a result 
of the two highest-scoring protocols being developed in 2004 and 2005.  
We did not see any differences in PRO protocol checklist score for type of sponsorship or whether 
the trial was international or national. We did not have sufficient study power to explore the impact 
of these variables in a multivariate model, yet there may be some interplay between these variables. 
Therefore this may be an interesting direction for future research with a larger sample size.  
Our findings reinforce the need for clear, PRO-specific protocol guidance to standardise PRO 
methodology, improve PRO data quality and minimise the potential for bias. The modern push to 
publish trial protocols may persuade investigators to seek guidance for protocol development and 
planning of PRO studies. Publication also limits opportunity for post-hoc PRO analysis plans, as 
readers may verify pre-specified methodologies and analyses against those published in final 
manuscripts [21,22]. A recent review of British Medical Journal trial publications (September 2013-
July 2014) found 22% of pre-specified outcomes were not reported and 8% of reported trial 
outcomes were not pre-specified[22]. Additionally, clear protocol guidance is likely to improve 
methodology and minimise rates of missing PRO data[18]. Recent estimates suggest approximately 
20% of oncology RCTs that include a PRO endpoint in the protocol go on to publish PRO findings[23] 
thereby wasting research resources and participants’ time [24]. The reasons for failing to publish 
PRO data may vary, however it is likely that many PRO studies go unpublished due to high rates of 
missing PRO data[25]. Although not all types of missing PRO data are preventable, strategies exist to 
minimise the impact of missing PRO data on data quality, and many of these must be planned and 
included in the protocol [18]. 
Strengths  
The PRO protocol checklist used in this study was developed based on a comprehensive systematic 
review of PRO protocol guidance[10], and has undergone preliminary refinement  by the ISOQOL 
Best Practices for PROs Taskforce. The final, internationally-endorsed PRO Protocol Checklist will be 
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a streamlined version of the one used in this study, with refinements based on expert and 
stakeholder consensus. Therefore a strongpoint of our study is that our results will be comparable to 
future studies evaluating protocol content. We calculated the percentage PRO protocol checklist 
score based only on applicable items for each protocol, enabling fair assessment and comparability 
across protocols. Two authors independently reviewed each protocol and inter-rater agreement was 
excellent.  
Limitations 
Despite our rigorous search strategy and persistent efforts contacting authors and engaging support 
from the GCIG, we were unable to obtain 37% of the 41 identified ovarian cancer trial protocols, as 
many trial authors were not responsive or contactable by email. This was expected, as the RCTs were 
published up to 16 years ago – a time when it was uncommon for protocols to be published. It is 
possible that protocol content of our cohort may not be representative of the overall standard of 
ovarian cancer protocols. 
The protocol checklist used is very comprehensive and not all items are essential for all PRO 
endpoints; this should be taken into account when interpreting the results of the study.  The final 
version of the PRO protocol checklist will clarify essential items, based on Delphi consensus of key, 
international stakeholders. We anticipate this checklist will be available in 2018.  Lessons learned 
from this study have been logged and will feed into future development of the PRO protocol 
checklist via the ISOQOL Best Practices for PROs Taskforce. 
We did not assess the quality of protocol content or suitability of chosen methodology to study aims; 
rather we used an objective approach and assessed whether checklist items were addressed 
partially or fully in protocols. We also did not collect information about whether other forms of 
guidance to complement the protocol, for example study coordinators’ manuals or statistical 
analysis plans, were used. It is possible that other forms of guidance were used and these may have 
described some aspects of the PRO methodology in more detail, beyond the description provided in 
protocols.   
Conclusions and next steps 
PRO sections of ovarian cancer RCT protocols varied in comprehensiveness; however on average less 
than one-third of recommended PRO protocol checklist items were addressed. In some cases, 
guidance regarding PRO administration was lacking, which may lead to inconsistent and sub-optimal 
PRO methodology, and consequently sub-optimal PRO data quality. Our review highlights the need 
for comprehensive and clear PRO-specific content of RCT protocols; in particular, a need to specify 
and justify PRO assessment time points, PRO administration procedures, approaches to minimise 
and handle missing PRO data; and plans for scoring and analysing PRO data. Research into impact of 
PRO-specific content of the studied protocols on reporting and the rates of missing PRO data is 
ongoing. Clear guidance for PRO-specific content of protocols is needed in order to improve the 
standard of PRO endpoints in ovarian cancer trials.   
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Table 1. Characteristics of the 26 ovarian cancer RCT protocols1 
Characteristic No. of protocols (%) 
Year of development 1995 – 2000 10 (38) 
 2001 - 2005 10 (38) 
 2006 - 2010 4 (15) 
 Unclear from protocol 2 (8) 
Recruitment International recruitment (i.e. >1 country) 11 (42) 
 National recruitment 7 (27) 
 Unclear if international recruitment 8 (31) 
Intervention Chemotherapy 21 (81) 
 Targeted therapy 5 (19) 
 Surgery 1 (4) 
Primary endpoint Progression-free survival (PFS) 15 (58) 
 Overall survival 3 (12) 
 Survival (other) 3 (12) 
 All-cause mortality 2 (8) 
 PFS and QOL (co-primary) 1 (4) 
PRO endpoint status Co-primary 1 (4) 
 Secondary 24 (92) 
 Unclear from protocol 1 (4) 
PRO measures used EORTC QLQ-C30 2 19 (73) 
 EORTC QLQ-OV28 3 11 (42) 
 FACT-O 4 6 (23) 
 Other FACIT 5 measures 3 (12) 
 EQ-5D6 3 (12) 
 Other 3 (12) 
Sponsors Clinical Trials Group 19 (73) 
 Commercial/pharmaceutical 3 (12) 
 Co-sponsored: Trials group and commercial 3 (12) 
 Unclear 1 (4) 
1RCTs are not identified in this manuscript as per agreement with the RCT authors. 2 European Organisation for Research 
and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30); 3 ovarian cancer module (QLQ-OV28),  
which is used with the QLQ-C30; 4 Functional Assessment of Cancer Therapy – Ovarian Cancer Module (FACT-O); 5 
Functional Assessment of Cancer Therapy (FACIT); 6 the EuroQOL-5 dimensions (EQ-5D). 
  
Table 2. Total PRO protocol checklist score of 26 ovarian cancer RCT protocols 
 n Mean (SD) total 
score 
Mean total 
score % 
Total score (lowest - 
highest extreme) 
Protocols with 54 applicable PRO 
checklist items 
14 13.8 (7.0) 25.6 4.5 - 27 
Protocols with 55 applicable PRO 
checklist items 
12 17.4 (7.8) 31.6 7 - 36 
All protocols 26 15.5 (7.5) 28.4 4.5 - 36 
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P56. Plans for regular feedback to participants
P53. Plan for consistent/standardised management of PRO alerts
P29. Order of PRO measures standardised or randomised
P55. Will PRO forms will be used to influence patient care?
P48. Sequence of testing/exploratory analyses to control  multiplicity
P40. Assumptions of PRO analyses
P30. Plan for systematically training data collection personnel
P20. Evidence of measurement equiv./cross‐cultural validity
P8. Is PRO completion pre‐randomisation eligibility requirement?
P7. Inclusion/exclusion criteria for PRO endpoint(s)
P54. Describe informed consent procedure for PRO assessment.
P52. Describe  role of the Data Monitoring Committee
P35. Procedures for maintaining electronic PRO system/database
P6. Sampling method (if PROs collected in subset of trial sample)
P42. Include an a priori estimation of PRO effect size
P41. Anticipated response rate and implications for sample size
P38. Instructions consistent with questionnaire user manual
P36. Plan for monitoring PRO compliance, including time windows
P24. How PRO will be completed  (pencil & paper, online, etc)
P37. PRO administration, handling/transmission & storage procedures
P5. PRO hypothesis
P51. Describe method for handling missing assessments
P45. Minimum PRO response rate
P44. Include a priori identified summary statistics
P34. Staff position responsible at each centre (&/or centrally)
P28. Describe what type and level of assistance is acceptable
P16. Justify the timing of PRO assessments
P1. Personnel responsible for PRO components of trial
P32. Guidance on discussing importance of PROs with patient
P22. Estimated time to complete each assessment, and feasibility
P14.Targeted & acceptable time windows for PRO assessments
P43. Specify intention‐to‐treat or per‐protocol PRO analyses
P17. Required PRO sample size
P4. PRO study objective
P50. State how missing data will be described
P47. Statistical significance levels and plans for multiplicity
P33. Procedures for patients who withdraw or stop treatment early
P31. Procedures to minimise missing data
P49. Specify the criteria for clinical significance
P27. Specify who will administer the PRO measure
P11. Specify the timepoint(s) for PRO analysis and rationale
P2. Describe what is currently known/gaps in PRO literature
P25. Where PROM will be completed (clinic, at home, etc)
P23. Include a pre‐specified data collection plan
P46. Methods for scoring endpoints
P15. Timing of PRO assessment (e.g. before clinical assessments)
P13. Specify if baseline PRO completed before randomisation
P19. Justify choice of PRO Measure
P3. Rationale for inclusion of PROs
P39. Planned PRO analyses
P64. Provide references to support key PRO statements
P10. Describe  PRO constructs used to evaluate the intervention
P63. Identify PRO sections of the protocol in the table of contents
P18. Describe the PRO Measure
P9. Identify PRO endpoint as  primary, secondary, exploratory
P12. PRO assessments in the main schedule of assessments
% fully addressed % partially addressed
Appendix 1. Search strategy 
Rebecca Mercieca-Bebber, Michael Friedlander, Peey-Sei Kok, Melanie Calvert, Derek Kyte, Martin Stockler, 
Madeleine T. King. The patient-reported outcome content of international ovarian cancer randomised 
controlled trial protocols. 
Medline OVID 1/2/2016 
 Ovarian cancer terms  
1 (ovar* adj (neoplasm$ or cancer or carcinoma or tumo$ or malignan$)).tw. 49275 
2 Ovarian neoplasms.sh. 67150 
 QOL/patient-reported outcome terms  
3 self-report*.tw. 87069 
4 Quality of life.sh. 131753 
5 Quality of life.tw. 152958 
6 "health status".tw. 37664 
7 'health utilit*'.tw. 1140 
8 'symptom assessment'.tw. 1445 
9 physical function*.tw. 13473 
10 social function*.tw. 9121 
11 "social wellbeing".tw. 134 
12 'sexual function*'.tw. 9161 
13 PRO.tw. 115062 
14 PROM.tw. 1390 
15 HRQOL.tw. 8025 
16 HRQL.tw. 2411 
17 QOL.tw. 20265 
18 QL.tw. 1078 
19 "functional status".tw. 17166 
20 (symptom* adj (improv$ or change$ or deteriorat$ or assessment$ or burden or distress)).tw. 15265 
21 Questionnaire*.tw. 308065 
22 Survey.tw. 325454 
 Trial terms  
23 "trial".tw. 367927 
24 RCT.tw. 9071 
25 randomi$ study.tw. 23300 
 Groupings  
26 1 or 2 75642 
27 or/3-22 936149 
28 23 or 24 or 25 390904 
29 26 and 27 and 28 349 
30 limit 29 to (english language and yr="2000 -Current") 308 
31 26 and 27 2913 
32 limit 31 to (clinical study or clinical trial, phase iii or clinical trial or controlled clinical trial) 160 
33 limit 32 to (english language and yr="2000 -Current") 111 
34 30 and 33 66 
35 30 or 33 353 
 
 
 
  
Cochrane central register for controlled trials 1/2/2016 
 
Searches Results 
1 (ovar* adj (neoplasm$ or cancer or carcinoma or tumo$ or malignan$)).tw. 2506 
2 Ovarian neoplasms.sh. 1053 
3 self-report*.tw. 11240 
4 Quality of life.sh. 12973 
5 Quality of life.tw. 28934 
6 "health status".tw. 2981 
7 'health utilit*'.tw. 220 
8 'symptom assessment'.tw. 286 
9 physical function*.tw. 3362 
10 social function*.tw. 1594 
11 "social wellbeing".tw. 16 
12 'sexual function*'.tw. 1336 
13 PRO.tw. 3578 
14 PROM.tw. 221 
15 HRQOL.tw. 1572 
16 HRQL.tw. 485 
17 QOL.tw. 5175 
18 QL.tw. 180 
19 "functional status".tw. 1896 
20 (symptom* adj (improv$ or change$ or deteriorat$ or assessment$ or 
burden or distress)).tw. 
4663 
21 Questionnaire*.tw. 33367 
22 Survey.tw. 8356 
23 1 or 2 2681 
24 or/3-22 79824 
25 23 and 24 278 
26 limit 25 to (english language and yr="2000 -Current") 216 
 
Appendix 2. PRO protocol checklist 
Rebecca Mercieca-Bebber, Michael Friedlander, Peey-Sei Kok, Melanie Calvert, Derek Kyte, Martin Stockler, 
Madeleine T. King. The patient-reported outcome content of international ovarian cancer randomised 
controlled trial protocols. 
 
  PRO Protocol checklist item 
P1 List personnel responsible for  PRO components of trial  
P2 Describe what is currently known about PROs in this area and explain the gaps in literature 
P3 Provide a rationale for the inclusion of PROs as appropriate to the study population, intervention, 
context, objectives and setting 
P4 State the PRO study objective in relation to PRO domain/s, patient population and timeframe 
P5 State the PRO hypothesis & corresponding null hypothesis and to which outcome(s) the hypothesis 
relates 
  Methods 
P6* If PROs will be collected in a subset of the study population or in specific centres, include a 
description/rationale for the sampling method  
P7 State the inclusion/exclusion criteria for PRO endpoint(s) (e.g., language/reading requirements) 
P8 Specify if PRO completion is pre-randomisation eligibility requirement 
P9 Identify the PRO endpoint as the primary, secondary (and if so - whether a key/important secondary), 
or an exploratory endpoint  
P10 Describe the PRO constructs used to evaluate the intervention e.g. overall QOL, specific domain, 
specific symptom 
P11 Specify the timepoint(s) for PRO analysis (including the principle timepoint of interest) and provide 
the rationale for these 
P12 Include PRO assessments in the main protocol schedule of assessments, specifying which PRO 
measures (PROMs) will be used at each assessment 
P13 Specify if baseline PRO assessment should be completed before randomisation 
P14 Specify the targeted time and acceptable  time windows for each PRO assessment 
P15 If PROs are to be completed in the clinic: specify timing of PROM delivery in relation to clinical 
assessments (e.g. before/whilst/after seeing clinician and/or clinical assessments)  
P16 Justify the timing of PRO assessments. Scheduled PRO assessments should link to research questions, 
hypotheses,  length of recall, disease/treatment  natural history, planned analysis and time of 
comparison must be comparable for both arms 
P17^  If PRO is the primary endpoint, state the required PRO sample size, otherwise discuss the power of the 
PRO analysis 
  PROM & administration 
P18 Describe the PROMs including, number of items/domains, instrument scaling/scoring, reliability, 
content and construct validity, responsiveness, sensitivity, acceptability, recall period. Provide 
references as appropriate 
P19 Justify choice of PROM(s)  by linking specific domains/items to clinical justifications and hypotheses   
P20 Provide evidence of measurement equivalence across modes (i.e., when mixing modes of PRO data 
collection) and/or of cross cultural validity where different language versions of  questionnaires are 
used 
P21* Outline plans for evaluation of measurement properties, if appropriate  (e.g. if not previously 
validated in the population of interest) 
P22 Specify the estimated time to complete each assessment, and discuss feasibility of assessment for the 
population" 
P23 Include a pre-specified data collection plan 
P24 Specify how PROM will be completed  (e.g. pencil and paper, online, etc) 
P25 Specify where PROM will be completed (e.g.  clinic, home, etc) 
  PRO Protocol checklist item 
P26* Where applicable, justify use of proxies (define conditions under which proxy assessment is 
permissible) 
P27 Specify who will administer the PROM (e.g., a physician, nurse, etc) 
P28 If it is permissible for another person to help the study participant complete the PROM, describe what 
type and level of assistance is acceptable  
P29* If more than one PROM will  be used, specify whether the order of administration will be 
standardised or randomised  
P30 Include a plan for systematically training and contacting local site personnel to ensure that they 
understand the content and importance of collecting PRO data.  Ideally coordinated by a lead data 
manager who monitors PRO completion rates in real time and communicates with sites if completion 
rates are suboptimal 
P31 Specify procedures for data collection and management methods to minimise missing data.  E.g. 
checking completed PROMs (including who will check forms and how will they deal with missing 
PROMs or missing items). 
P32 Include guidance on discussing importance of PROs with patient 
P33 Establish process for PRO assessment at (and beyond) withdrawal for patients who withdraw early 
from a study or who go 'off-study'/'off treatment' 
P34  Specify that a named person/position at each centre (and/or centrally) be nominated to take 
responsibility for administration, collection and checking of PROM - specify whether this is or is not 
the treating clinician 
  Data management 
P35 Specify how an electronic PRO system/database will be maintained and how investigator will meet 
regulatory requirements and ensure data integrity and security 
P36 Specify plan to monitor PRO compliance, including adherence to time windows 
P37 Include an overview of PRO administration (data collection), and data handling/transmission and 
storage procedures 
P38 Ensure plans for administration of PROM(s) are consistent with each PROM's user manual 
  Analyses 
P39 Include an a priori description of all planned PRO analyses pertaining to the study hypotheses 
P40 State the assumptions of PRO analyses 
P41 State the anticipated response rate and implications for the sample size  
P42 Include an a priori estimation of PRO effect size  
P43 Specify intention-to-treat or per-protocol PRO analyses. 
P44 Include a priori identified summary statistics (as appropriate)  
P45 Specify the minimum PRO response rate and acceptable degree of timing deviation (i.e acceptable 
time windows for each PRO assessment timepoint) before the PRO objective is compromised 
P46 Describe methods for scoring endpoints. Where possible, reference scoring manuals for summated 
scales from PROM (domain-specific &/or total) & methods for handling missing items, and 
methodological papers for composite endpoints (e.g. QTWiST) 
P47 State statistical significance levels and include plans for multiplicity/controlling type 1 error 
P48  Pre-specify  sequence of testing/exploratory analyses to control for multiplicity or pre-specify 
domains  (e.g. in a regulatory trial/labelling claim) (Common in pharma trials. Involves pre-specifying 
domains that alpha would be spent on, or ordering the domains in priority & alpha would be spent 
down the list) 
P49 Specify the criteria for clinical significance (e.g. state minimal [clinical] important difference and/or 
responder definition (size and duration of benefit)) 
P50 State how missing data will be described 
P51 Describe method for handling missing assessments (e.g. approach to imputation and sensitivity 
analyses) 
  Monitoring 
P52 Describe the role of the Data Monitoring Committee and Quality Assurance for PROs 
P53 Include an a priori plan for consistent/standardised management of PRO alerts (symptoms/issues 
  PRO Protocol checklist item 
reported by patients that exceed a pre-defined level of severity) to be clearly communicated to all 
appropriate trial staff 
P54 Describe informed consent procedure for PRO assessment. 
P55 Specify whether PRO forms will be used to influence therapy or patient management  
P56 Include detailed plans for regular feedback to participants via letter/newsletter on PRO aspect of 
study 
  General Approach to Protocol 
P63 Identify PRO sections of the protocol in the table of contents 
P64 Provide references to support key PRO statements 
*This item was N/A for some or all protocols 
^We assessed all protocols for this item regardless of PRO endpoint status 
 
Appendix 3. PRO protocol checklist scores over time  
Rebecca Mercieca-Bebber, Michael Friedlander, Peey-Sei Kok, Melanie Calvert, Derek Kyte, Martin 
Stockler, Madeleine T. King. The patient-reported outcome content of international ovarian cancer 
randomised controlled trial protocols.  
 
 
Note: year of protocol development was unclear for 2 protocols, therefore this plot includes PRO 
protocol checklist scores (%) for 24 ovarian cancer RCTs. There was a trend towards total PRO 
protocol checklist scores improving over time, however it was not statistically significant: r =0.37, 
p=0.07 [95% CI -0.35, 0.68]. 
 
